An enzyme immunoassay (EIA) for anti-hepatitis B core (HBc) immunoglobulin Gi (IgGl) was compared with a commercial radioimmunoassay (RIA) for anti-HBc antibody (Corab; Abbott Laboratories, North Chicago, 111.). In parallel tests of 445 consecutive samples, discrepant results were obtained with 2 samples, 1 of which was positive only by the RIA and the other of which was positive only by the EIA for anti-HBc IgG1. (Corab; Abbott) at different blood centers in central Sweden, gave low-level anti-HBc results and were sent to the Department of Virology for confirmation were used. These five groups of sera are referred to as the titrated sera, the consecutive sera, the low-level sera, the blood donor sera, and the reference sera, respectively.
The specificity of low-level results obtained by commercially available competitive assays for anti-hepatitis B core (HBc) antigen is a problem recognized by those engaged in the laboratory diagnosis of hepatitis B. However, this matter has been the subject of only a few reports. Studies approaching this problem have either been epidemiological (5, 25) or have aimed at demonstrating previous exposure to hepatitis B virus (HBV) by assessing a booster anti-hepatitis B surface (HBs) antigen response after vaccination against HBV (4; F. Bonino, G. Poli, A. Ponzetto, G. C. Acitis, M. Rizetto, and G. Verme, Hepatology 5:1041 Hepatology 5: , 1984 ). Both approaches have yielded results that render the specificity of some low-level results doubtful. There have been no previous attempts to determine to which immunoglobulin class and subclass low-level anti-HBc belongs. Immunoglobulin Gi (IgGl) is the dominating subclass of IgG in viral infections (12, 13, 16, 20, 21, 23) . Since this also holds true for anti-HBc in chronic HBV infections (18) we compared here an enzyme immunoassay (EIA) for anti-HBc IgG1 with a competitive assay for anti-HBc. We also investigated the possibility of using immunoglobulin class-and subclassspecific EIA procedures to confirm results obtained by competitive assays for anti-HBc.
MATERIALS AND METHODS Specimens. The (14) and anti-HBs (10), anti-HBc (17), and anti-HBc (7) IgM were determined by commercial assays (Abbott) as described previously. HBV DNA in serum was assayed by a dot blot procedure as described by Norder et al. (H. Norder, C. Brattstrom, and L. O. Magnius, J. Med. Virol., in press).
RESULTS
The performance of the EIA for anti-HBc IgGl, IgG3, IgAl, and IgM on the negative sera used for cutoff determinations is given in Table 1 . The relative sensitivity of the EIA for anti-HBc IgGl was 2 to 17 times higher than that of the RIA at the endpoint determination on the seven titrated serum samples (Table 2) .
On testing of the 445 consecutive serum specimens by the RIA and for anti-HBc IgGl, 74 were positive and 369 were negative by both assays. Two serum samples gave discordant results. One of the discordant serum samples was positive only by the RIA and one was positive only for anti-HBc IgGl. The sample that was positive only by the RIA was found to be positive for anti-HBc IgM and IgAl ( Table 3 ). The sample that was positive only for anti-HBc IgGl became exhausted and could not be tested further. When the 192 low-level serum samples were tested by the RIA and for anti-HBc IgGl, 151 were positive and 31 were negative by both assays and 10 gave discordant results. Of five discordant samples that were positive only by the RIA, two had detectable anti-HBc IgM, anti-HBc IgAl, or both ( Table 3) . Neither of these two samples had detectable anti-HBs. One sample, which gave 72% inhibition in the RIA, was negative in all confirmatory assays, including that for anti-HBs (Table 3 ). The remaining two samples had detectable anti-HBc IgG3 in combination with anti-HBs (Table 3 ). All five serum samples that were positive only for anti-HBc IgGl were positive for anti-HBs (Table 3) . Results obtained by the RIA for these five serum samples indicated that there was from 46 to 31% inhibition.
Of the 19 blood donor serum samples tested, 16 were found to be positive by the RIA in our laboratory. Of these 19 serum samples, 10, all of which were positive by the RIA, were positive for anti-HBc IgGl, anti-HBc IgG3, or both. Three of the blood donor serum samples were positive only by the RIA and for anti-HBc IgM, anti-HBc IgAl, or both. Anti-HBc IgM was found in one sample that was negative by the RIA. Five samples, three of which were positive by the RIA, were negative for anti-HBc IgG1, IgG3, IgM, and IgAl and for anti-HBs (Table 3) . The results from the determination of the classes and subclasses of anti-HBc in the 10 blood donor serum samples that were negative for anti-HBs are given in Table 3 .
Two of the seven reference serum samples were positive for anti-HBc IgGl. The results for the remaining five serum samples are given in Table 3 . All discrepant samples were negative for HBs antigen by the RIA and for HBV DNA by the dot blot hybridization assay.
The results concerning the classes and subclasses of anti-HBc for all investigated discrepant samples in relation (19) . However, we suggest that low-level anti-HBc with IgM and IgAl reactivity may be secondary to other immunological stimuli than HBV, such as another infection activating B cells to produce anti-HBc. This might explain why, on repeated testing of individuals with low-level antiHBc, it has been found that they tend to become negative for anti-HBc with time (5).
In addition to being a T-cell-dependent antigen, the HBc antigen may also be a T-cell-independent antigen (15) . Therefore, unspecific activation of immature B cells capable of producing anti-HBc IgM might result in a positive antiHBc test, which would not be indicative of exposure to HBV. In mice anti-HBc IgM production is T cell independent, but the switch from IgM to IgG is T cell dependent (15) . Thus, HBc antigen-activated T cells should be a prerequisite for anti-HBc IgG production. It is therefore most likely that the presence of anti-HBc IgGl and anti-HBc IgG3, which requires a differentiated plasma cell, in contrast to the presence ofanti-HBc IgM and anti-HBc IgAl, is a sign of previous exposure to HBV. Since IgGl is the quantitatively dominating subclass of IgG directed to HBc antigen (18) , this subclass is best suited for specificity confirmation of anti-HBc results from competitive assays. In three individuals with low-level anti-HBc in our study, the anti-HBc IgM and anti-HBc IgAl response was secondary to an acute or reactivated Epstein-Barr virus infection. IgA has been shown to be the next most responsible immunoglobulin after IgM for the elevation of total immunoglobulin levels in infectious mononucleosis caused by Epstein-Barr virus (2) .
The regulation of the two IgA subclasses has been shown to be less T cell dependent than that of the IgG subclasses (3). It has been claimed that before complete maturation is attained, B cells are susceptible to antigenic or mitogenic stimulation, which may give rise to IgM production, IgA production, or both but not to production of any of the IgG subclasses (24 Testing for anti-HBc is currently being introduced at different blood centers worldwide, not only to reduce HBVrelated posttransfusion hepatitis but also to identify blood donors who might be or become infected with other bloodtransmitted agents, such as human immunodeficiency virus and non-A, non-B hepatitis virus. The specificity of antiHBc tests with regard to HBV exposure is thus very important not only for economic reasons but also because the exclusion of blood donors on the basis of false anti-HBc results, i.e., results not indicative of HBV exposure, can be psychologically harmful. Of 19 blood donors diagnosed as being anti-HBc positive by the EIA (Organon), only 10 were found to have been previously exposed to HBV, according to our results. In our series, the false-positive rate for the anti-HBc EIA (Organon) was thus 9 of 19 (47%). This might be compared with the similar proportion reported by Hanson and Polesky (6) Kline et al. (8) found that the prevalence rate of anti-HBc was 2.36%, with a range from 0.55 to 6.38%. In lowprevalence areas, the false-positive rate of anti-HBc may be close to the recorded positive rate, and any possible relation between HBV and other blood-transmitted agents causing posttransfusion hepatitis is likely to be overshadowed. Thus, the relative frequency of false-positive anti-HBc results may vary considerably among different areas. This may explain why conclusions drawn from studies at different blood centers have been conflicting regarding the value of antiHBc as a surrogate test for reducing the incidence of non-A, non-B-related posttransfusion hepatitis (1, 8, 9, 22, 26) . Reports relating anti-HBc to other blood-borne infections must be reevaluated in light of our findings of the significance of low-level results of anti-HBc assays.
